- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma ; volume:8 ; number:1 ; day:22 ; month:12 ; year:2017 ; pages:1-13 ; date:12.2017
Nature Communications ; 8, Heft 1 (22.12.2017), 1-13, 12.2017
- Creator
-
Bertrand, Florie
Montfort, Anne
Marcheteau, Elie
Imbert, Caroline
Gilhodes, Julia
Filleron, Thomas
Rochaix, Philippe
Andrieu-Abadie, Nathalie
Levade, Thierry
Meyer, Nicolas
Colacios, Céline
Ségui, Bruno
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-017-02358-7
- URN
-
urn:nbn:de:101:1-2019070801491576996156
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.20242024, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bertrand, Florie
- Montfort, Anne
- Marcheteau, Elie
- Imbert, Caroline
- Gilhodes, Julia
- Filleron, Thomas
- Rochaix, Philippe
- Andrieu-Abadie, Nathalie
- Levade, Thierry
- Meyer, Nicolas
- Colacios, Céline
- Ségui, Bruno
- SpringerLink (Online service)
Other Objects (12)
Management of Localized Melanoma in the Anti-PD-1 Era
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
Management of Localized Melanoma in the Anti-PD-1 Era
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
Management of Localized Melanoma in the Anti-PD-1 Era
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma